Junfeng Qiu
YOU?
Author Swipe
View article: Hedyotis diffusae herba -Scutellaria Barbata herba drug pair suppresses prostate cancer by inducing apoptosis
Hedyotis diffusae herba -Scutellaria Barbata herba drug pair suppresses prostate cancer by inducing apoptosis Open
Prostate cancer (PCa), a globally prevalent male malignancy, necessitates breakthroughs in treating its hormone-refractory stage. The Traditional Chinese Medicine drug pair Hedyotis Diffusae Herba - Scutellaria Barbatae Herba (HDH-SBH) sho…
View article: Unravelling targeted therapy in prostate cancer: from molecular mechanisms to translational opportunities
Unravelling targeted therapy in prostate cancer: from molecular mechanisms to translational opportunities Open
Prostate cancer, ranking among the most prevalent malignancies in males worldwide, is undergoing a significant evolution in therapeutic paradigms from conventional approaches to precision medicine, with recent advances in targeted therapie…
View article: Systems Pharmacology and Molecular Dynamics Elucidate Hedyotis Diffusae Herba - Scuttellaria Barbatae Herba Drug Pair Synergistically Suppresses Prostate Cancer via Apoptosis Signaling Axis
Systems Pharmacology and Molecular Dynamics Elucidate Hedyotis Diffusae Herba - Scuttellaria Barbatae Herba Drug Pair Synergistically Suppresses Prostate Cancer via Apoptosis Signaling Axis Open
Prostate cancer (PCa), a globally prevalent male malignancy, necessitates breakthroughs in treating its hormone-refractory stage. The Traditional Chinese Medicine drug pair Hedyotis Diffusae Herba – Scutellaria Barbatae Herba (HDH–SBH) sho…
View article: Identification of Systemic Drug Targets for Anti-cavernous Fibrosis in the Treatment of Erectile Dysfunction, Guided by Genome-Wide Mendelian Randomization
Identification of Systemic Drug Targets for Anti-cavernous Fibrosis in the Treatment of Erectile Dysfunction, Guided by Genome-Wide Mendelian Randomization Open
The treatment of erectile dysfunction (ED) remains a significant challenge. Mendelian randomization (MR) is being increasingly utilized to identify novel therapeutic targets. In this study, we carried out a genome-wide MR analysis on drugg…
View article: The Effects of Xialiqi Capsules in Regulating the Pyroptosis of Prostate Epithelial Cells Via NLRP3/Caspase-1 Pathway for the Treatment of Chronic Prostatitis
The Effects of Xialiqi Capsules in Regulating the Pyroptosis of Prostate Epithelial Cells Via NLRP3/Caspase-1 Pathway for the Treatment of Chronic Prostatitis Open
Chronic prostatitis (CNP) is a prevalent inflammatory disorder among men. The Xialiqi capsule has been reported to alleviate the clinical symptoms of CNP patients, which may be related to its anti-inflammatory effect; yet, its exact mechan…
View article: Exploration of the Concept and Path of Traditional Chinese Medicine Health Culture Leading the "New Healthy Lifestyle"
Exploration of the Concept and Path of Traditional Chinese Medicine Health Culture Leading the "New Healthy Lifestyle" Open
This paper deeply analyzes the connotation of traditional Chinese medicine health culture and the "new healthy lifestyle", and explores how the concepts of "harmony between man and nature", "balance of yin and yang", "syndrome differentiat…
View article: PREX2 contributes to radiation resistance by inhibiting radiotherapy-induced tumor immunogenicity via cGAS/STING/IFNs pathway in colorectal cancer
PREX2 contributes to radiation resistance by inhibiting radiotherapy-induced tumor immunogenicity via cGAS/STING/IFNs pathway in colorectal cancer Open
Background Colorectal cancer (CRC) lacks established biomarkers or molecular targets for predicting or enhancing radiation response. Phosphatidylinositol-3,4,5-triphosphate-dependent Rac exchange factor 2 (PREX2) exhibits intricate implica…
View article: Astragaloside IV-PESV Repressed T Cell Immunosuppression by Inhibiting PD-L1 Expression in Prostate Cancer through STAT3 Pathway
Astragaloside IV-PESV Repressed T Cell Immunosuppression by Inhibiting PD-L1 Expression in Prostate Cancer through STAT3 Pathway Open
Background. Prostate cancer (PCa) is a major threat to men’s health worldwide, and there is an urgent need to find a supportive strategy to improve traditional PD-1/PD-L1 targeted immunotherapy. Our previous research identified astragalosi…
View article: Effectiveness of non-pharmaceutical intervention on sperm quality: a systematic review and network meta-analysis
Effectiveness of non-pharmaceutical intervention on sperm quality: a systematic review and network meta-analysis Open
Infertility affects about 10% of the world's population and has been recognized by the WHO as a global public health problem. The aim of this network meta-analysis was to investigate the efficacy of non-pharmaceutical interventions on sper…
View article: Data from Downregulation of <i>SAFB</i> Sustains the NF-<b>κ</b>B Pathway by Targeting <i>TAK1</i> during the Progression of Colorectal Cancer
Data from Downregulation of <i>SAFB</i> Sustains the NF-<b>κ</b>B Pathway by Targeting <i>TAK1</i> during the Progression of Colorectal Cancer Open
Purpose: To investigate the role and the underlying mechanism of scaffold attachment factor B (SAFB) in the progression of colorectal cancer (CRC).Experimental Design: SAFB expression was analyzed in the Cancer Outlier Profile Analysis of …
View article: Data from Downregulation of <i>SAFB</i> Sustains the NF-<b>κ</b>B Pathway by Targeting <i>TAK1</i> during the Progression of Colorectal Cancer
Data from Downregulation of <i>SAFB</i> Sustains the NF-<b>κ</b>B Pathway by Targeting <i>TAK1</i> during the Progression of Colorectal Cancer Open
Purpose: To investigate the role and the underlying mechanism of scaffold attachment factor B (SAFB) in the progression of colorectal cancer (CRC).Experimental Design: SAFB expression was analyzed in the Cancer Outlier Profile Analysis of …
View article: Figure S2 from Downregulation of <i>SAFB</i> Sustains the NF-<b>κ</b>B Pathway by Targeting <i>TAK1</i> during the Progression of Colorectal Cancer
Figure S2 from Downregulation of <i>SAFB</i> Sustains the NF-<b>κ</b>B Pathway by Targeting <i>TAK1</i> during the Progression of Colorectal Cancer Open
Figure S2 shows that down-regulation of SAFB activated NF-κB signaling pathway
View article: Figure S5 from Downregulation of <i>SAFB</i> Sustains the NF-<b>κ</b>B Pathway by Targeting <i>TAK1</i> during the Progression of Colorectal Cancer
Figure S5 from Downregulation of <i>SAFB</i> Sustains the NF-<b>κ</b>B Pathway by Targeting <i>TAK1</i> during the Progression of Colorectal Cancer Open
Figure S5 shows that up-regulation of SAFB inhibited metastasis and angiogenesis in CRC through the SAFB-TAK1-NF-κB axis.
View article: Figure S1 from Downregulation of <i>SAFB</i> Sustains the NF-<b>κ</b>B Pathway by Targeting <i>TAK1</i> during the Progression of Colorectal Cancer
Figure S1 from Downregulation of <i>SAFB</i> Sustains the NF-<b>κ</b>B Pathway by Targeting <i>TAK1</i> during the Progression of Colorectal Cancer Open
Figure S1 shows that expression of SAFB in public databases and human CRC tissue
View article: Figure S3 from Downregulation of <i>SAFB</i> Sustains the NF-<b>κ</b>B Pathway by Targeting <i>TAK1</i> during the Progression of Colorectal Cancer
Figure S3 from Downregulation of <i>SAFB</i> Sustains the NF-<b>κ</b>B Pathway by Targeting <i>TAK1</i> during the Progression of Colorectal Cancer Open
Figure S3 shows that down-regulation of SAFB enhanced the activity of NF-κB signaling pathway by relieving transcription repression against TAK1
View article: Figure S3 from Downregulation of <i>SAFB</i> Sustains the NF-<b>κ</b>B Pathway by Targeting <i>TAK1</i> during the Progression of Colorectal Cancer
Figure S3 from Downregulation of <i>SAFB</i> Sustains the NF-<b>κ</b>B Pathway by Targeting <i>TAK1</i> during the Progression of Colorectal Cancer Open
Figure S3 shows that down-regulation of SAFB enhanced the activity of NF-κB signaling pathway by relieving transcription repression against TAK1
View article: Figure S1 from Downregulation of <i>SAFB</i> Sustains the NF-<b>κ</b>B Pathway by Targeting <i>TAK1</i> during the Progression of Colorectal Cancer
Figure S1 from Downregulation of <i>SAFB</i> Sustains the NF-<b>κ</b>B Pathway by Targeting <i>TAK1</i> during the Progression of Colorectal Cancer Open
Figure S1 shows that expression of SAFB in public databases and human CRC tissue
View article: Supplementary materials, methods and tables from Downregulation of <i>SAFB</i> Sustains the NF-<b>κ</b>B Pathway by Targeting <i>TAK1</i> during the Progression of Colorectal Cancer
Supplementary materials, methods and tables from Downregulation of <i>SAFB</i> Sustains the NF-<b>κ</b>B Pathway by Targeting <i>TAK1</i> during the Progression of Colorectal Cancer Open
Supplementary materials, methods and tables
View article: Figure S6 from Downregulation of <i>SAFB</i> Sustains the NF-<b>κ</b>B Pathway by Targeting <i>TAK1</i> during the Progression of Colorectal Cancer
Figure S6 from Downregulation of <i>SAFB</i> Sustains the NF-<b>κ</b>B Pathway by Targeting <i>TAK1</i> during the Progression of Colorectal Cancer Open
Figure S6 shows that expression of SAFB in CRC tissue was negatively correlated with that of TAK1 and NF-κB-related genes.
View article: Supplementary materials, methods and tables from Downregulation of <i>SAFB</i> Sustains the NF-<b>κ</b>B Pathway by Targeting <i>TAK1</i> during the Progression of Colorectal Cancer
Supplementary materials, methods and tables from Downregulation of <i>SAFB</i> Sustains the NF-<b>κ</b>B Pathway by Targeting <i>TAK1</i> during the Progression of Colorectal Cancer Open
Supplementary materials, methods and tables
View article: Figure S5 from Downregulation of <i>SAFB</i> Sustains the NF-<b>κ</b>B Pathway by Targeting <i>TAK1</i> during the Progression of Colorectal Cancer
Figure S5 from Downregulation of <i>SAFB</i> Sustains the NF-<b>κ</b>B Pathway by Targeting <i>TAK1</i> during the Progression of Colorectal Cancer Open
Figure S5 shows that up-regulation of SAFB inhibited metastasis and angiogenesis in CRC through the SAFB-TAK1-NF-κB axis.
View article: Figure S6 from Downregulation of <i>SAFB</i> Sustains the NF-<b>κ</b>B Pathway by Targeting <i>TAK1</i> during the Progression of Colorectal Cancer
Figure S6 from Downregulation of <i>SAFB</i> Sustains the NF-<b>κ</b>B Pathway by Targeting <i>TAK1</i> during the Progression of Colorectal Cancer Open
Figure S6 shows that expression of SAFB in CRC tissue was negatively correlated with that of TAK1 and NF-κB-related genes.
View article: Figure S4 from Downregulation of <i>SAFB</i> Sustains the NF-<b>κ</b>B Pathway by Targeting <i>TAK1</i> during the Progression of Colorectal Cancer
Figure S4 from Downregulation of <i>SAFB</i> Sustains the NF-<b>κ</b>B Pathway by Targeting <i>TAK1</i> during the Progression of Colorectal Cancer Open
Figure S4 shows that down-regulation of SAFB contributed to the aggressive features of CRC cells through the SAFB-TAK1-NF-κB axis.
View article: Figure S2 from Downregulation of <i>SAFB</i> Sustains the NF-<b>κ</b>B Pathway by Targeting <i>TAK1</i> during the Progression of Colorectal Cancer
Figure S2 from Downregulation of <i>SAFB</i> Sustains the NF-<b>κ</b>B Pathway by Targeting <i>TAK1</i> during the Progression of Colorectal Cancer Open
Figure S2 shows that down-regulation of SAFB activated NF-κB signaling pathway